[1]李　晓,马利军,张晓菊,等.非小细胞肺癌患者经支气管内超声引导支气管针穿刺获取的转移淋巴结标本与原发病灶标本中表皮生长因子受体基因突变比较[J].新乡医学院学报,2017,34(6):478-481.[doi:10.7683/xxyxyxb.2017.06.006]
　LI Xiao,MA Li-jun,ZHANG Xiao-ju,et al.Comparison of epidermal growth factor receptor genetic mutation in primary tumor and metastatic lymph nodes acquired by endobronchial ultrasound-guided transbronchial needle aspiration of non-small cell lung cancer[J].Journal of Xinxiang Medical University,2017,34(6):478-481.[doi:10.7683/xxyxyxb.2017.06.006]
点击复制

非小细胞肺癌患者经支气管内超声引导支气管针穿刺获取的转移淋巴结标本与原发病灶标本中表皮生长因子受体基因突变比较
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
34
期数:
2017年6
页码:
478-481
栏目:
临床研究
出版日期:
2017-06-05

文章信息/Info

Title:
Comparison of epidermal growth factor receptor genetic mutation in primary tumor and metastatic lymph nodes acquired by endobronchial ultrasound-guided transbronchial needle aspiration of non-small cell lung cancer
作者:
李　晓; 马利军; 张晓菊; 马　芸; 张茜茜; 潘金兵
（郑州大学人民医院呼吸与危重症医学科，河南　郑州　450003）
Author(s):
LI Xiao; MA Li-jun; ZHANG Xiao-ju; MA Yun; ZHANG Qian-qian; PAN Jin-bing
（Department of Respiratory and Critical Care Medicine，the People′s Hospital of Zhengzhou University，Zhengzhou 450003，Henan Province，China）
关键词:
非小细胞肺癌; 表皮生长因子受体; 突变; 经支气管超声引导针吸活检; 转移淋巴结
Keywords:
non-small cell lung cancer; epidermal growth factor receptor; mutation; endobronchial ultrasound-guided transbronchial needle aspiration; metastatic lymph node
分类号:
R734.2
DOI:
10.7683/xxyxyxb.2017.06.006
文献标志码:
A
摘要:
目的　比较晚期非鳞状非小细胞肺癌（NSCLC）患者经支气管内超声引导支气管针穿刺（EBUS-TBNA）获取的转移淋巴结（LN）标本与原发病灶（PT）标本的表皮生长因子受体（EGFR）突变状态，评价EBUS-TBNA获取标本用于检测EGFR基因突变的价值。方法　对2014年1月至2016年1月郑州大学人民医院收治的72例初治、非鳞状NSCLC患者（Ⅲ期和Ⅳ期）的PT标本与EBUS-TBNA获取的转移LN标本进行EGFR基因突变检测。通过扩增阻滞突变系统（ARMS）法检测 EGFR基因突变情况，比较EGFR基因突变的一致率，并评估不同EGFR基因突变患者靶向治疗的疾病控制率。结果　72例标本中，34例（47.2％）显示至少1个EGFR基因突变，其中PT标本33例，转移LN标本30例；主要是外显子19缺失和外显子21 L858R突变。PT和转移LN标本EGFR基因突变的一致率为88.9％（64/72）。1例患者的PT和转移LN标本中均有外显子21 L858R突变，而仅在转移LN标本中检测到T790M突变。EGFR基因突变的病例中有28例患者接受EGFR酪氨酸激酶抑制剂（TKI）治疗，其疾病控制率为71.4％（20/28，部分缓解16例，疾病稳定 4例）。PT和转移LN标本中EGFR基因突变一致患者和突变不一致患者的TKI治疗疾病控制率比较差异无统计学意义（χ2=0.07，P>0.05）。结论　通过EBUS-TBNA取得的转移LN标本的EGFR基因突变结果与同一患者的PT标本具有较高的一致性，晚期非鳞状NSCLC患者通过EBUS-TBNA获得的转移LN标本可以用于EGFR突变的检测。
Abstract:
Objective　To compare epidermal growth factor receptor genetic mutation in primary tumor and metastatic lymph nodes acquired via endobronchial ultrasound-guided transbronchial needle aspiration （EBUS-TBNA） in non-squamous，non-small cell lung cancer （NSCLC），in order to evaluated the efficacy of using EBUS-TBNA to obtain the samples in detecting epidermal growth factor receptor(EGFR) genetic mutation.Methods　Seventy-two treatment-naive，advanced，non-squamous NSCLC patients （stage Ⅲ and Ⅳ） with matched lymph node(LN) specimens obtained by EBUS-TBNA and primary tumor(PT) specimens from January 2014 to January 2016 in the People′s Hospital of Zhengzhou University were selected.EGFR genetic mutations were detected in patients with paired specimens through amplification refractory mutation system （ARMS）.The concordance rate of EGFR genetic mutations between LN and PT specimens were compared，and the disease control rate between patients with different EGFR genetic mutations was evaluated.Results　Of the 72 patients，at least one EGFR mutation was detected in 34 cases （47.2%），which included PT（n=33） and LN （n=30） specimens.Major mutations included exon 19 deletion and exon 21 L858R mutation.The concordance rate of EGFR mutations between matched PT and LN specimens was 88.9％（64/72）.T790M was detected in LN specimen only in one case with L858R in LN and PT.Moreover，28 patients with any mutation were treated with EGFR TKI.The disease control rate was 71.4％（20/28，16 patients with partial response and 4 patients with stable disease）.There was no significant difference in the disease control rate between the concordant mutation patients and the discordant mutation patients （χ2=0.07，P>0.05）.Conclusion　A high concordance rate of EGFR mutations of PT and matched LN specimens offered by EBUS-TBNA is observed，it demonstrates that LN samples obtained by EBUS-TBNA from advanced non-squamous NSCLC patients can be effectively used for EGFR mutation testing.

参考文献/References:

［1］　GAO G，REN S，LI A，et al.Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR：a meta-analysis from six phase III randomized controlled trials［J］.Int J Cancer，2012，131（5）：E822-E829.
［2］　NAVANI N，BROWN J M，NANKIVELL M，et al.Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer：a multicenter study of 774 patients［J］.Am J Resp Crit Care，2012，185（12）：1316-1322.
［3］　NGUYEN K S H，KOBAYASHI S，COSTA D B.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway［J］.Clin Lung Cancer，2009，10（4）：281-289.
［4］　SHIMIZU K，YUKAWA T，HIRAMI Y，et al.Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer［J］.Target Oncol，2013，8（4）：237-242.
［5］　OKADA H，ANAYAMA T，KUME M，et al.Comparison of epidermal growth factor receptor mutation analysis results between surgically resected primary lung cancer and metastatic lymph nodes obtained by endobronchial ultrasound-guided transbronchial needle aspiration［J］.Thorac Cancer，2012，3（3）：262-268.
［6］　YARMUS L B，AKULIAN J，LECHTZIN N，et al.Comparison of 21-gauge and 22-gauge aspiration needle in endobronchial ultrasound-guided transbronchial needle aspiration：results of the American college of chest physicians quality improvement registry，education，and evaluation registry［J］.Chest，2013，143（4）：1036-1043.
［7］　NAKAJIMA T，YASUFUKU K，NAKAGAWARA A，et al.Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration［J］.Chest，2011，140（5）：1319-1324.
［8］　LEE H S，LEE G K，LEE H S，et al.Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer：how many aspirations per target lymph node station［J］.Chest，2008，134（2）：368-374.
［9］　KIM H J，LEE K Y，KIM Y C，et al.Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer［J］.Lung Cancer，2012，75（3）：321-325.
［10］　GERLINGER M，ROWAN A J，HORSWELL S，et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing［J］.N Engl J Med，2012，2012（366）：883-892.
［11］　BAI H，WANG Z，CHEN K，et al.Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer［J］.J Clin Oncol，2012，30（25）：3077-3083.
［12］　WEI B，YANG K，ZHAO J，et al.Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer［J］.J Exp Clin Canc Res，2014，33（1）：5.
［13］　PARK S，HOLMES-TISCH A J，SHIM Y M，et al.Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer［J］.J Thorac Oncol，2009，4（7）：809-815.
［14］　MAHESWARAN S，SEQUIST L V，NAGRATH S，et al.Detection of mutations in EGFR in circulating lung-cancer cells［J］.New Engl J Med，2008，359（4）：366-377.

相似文献/References:

[1]张开普.介入治疗局部晚期非小细胞肺癌42例[J].新乡医学院学报,2002,19(05):421.
[2]牛红蕊,袁 亮,吴随群.羟基喜树碱联合顺铂和足叶乙甙治疗中晚期非小细胞肺癌39例[J].新乡医学院学报,2002,19(05):419.
[3]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌l7例[J].新乡医学院学报,2003,20(02):126.
[4]赫鸿昌.异长春花碱联合顺铂治疗晚期非小细胞肺癌17 例[J].新乡医学院学报,2003,20(02):126.
[5]张海君,闫卫东,邝先奎.目的从伦理学的角度来思考基因歧视产生的原因和所引起的危害，并寻求对策。方法查阅并分析近1O年的文献。结果导致基因歧视产生的理论观点是不正确的，这种现象对人类有极大的危害，人们可以通过对隐私权的保护来避免或减轻它对人类的伤害。结论 基因歧视是不公正也是不[J].新乡医学院学报,2003,20(06):428.
[6]蔡新华,张钦宪,唐亮,等.表皮生长因子受体靶向重组T7噬菌体抗肿瘤疫苗的免疫活性[J].新乡医学院学报,2005,22(03):188.
[7]曹名波,邹百仓,秦　斌.荆花胃康胶丸对实验性胃溃疡大鼠粘膜愈合和EGF、EGFR表达的影响[J].新乡医学院学报,2006,23(05):478.
[8]杨廷桐,李秀杰,武俊芳,等.端粒酶反转录酶活化与p53金属蛋白酶-9表达对非小细胞肺癌发生的影响[J].新乡医学院学报,2007,24(05):000.
[9]杨廷桐,武俊芳,李秀杰,等.非小细胞肺癌中p14ARF和mtp53蛋白表达与临床病理参数的关系[J].新乡医学院学报,2008,25(04):336.
[10]姬明丽,千智斌,徐自超.p53蛋白与非小细胞肺癌多药耐药性的关系[J].新乡医学院学报,2008,25(01):013.

更新日期/Last Update: 2017-06-05